Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

NCT06736418 is registered in ClinicalTrials.gov with Abdera Therapeutics Inc. as lead sponsor.

NCT NCT06736418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy
Lead sponsor
Abdera Therapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 10, 2025
Completion date
January 31, 2027
Enrollment
17 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

large cell neuroendocrine carcinoma of the lung, small-cell lung cancer (sclc)